Cytarabine monophosphate prodrugs
View Patent ↗Compounds of Formula I, their preparation and uses are described: wherein: M and V are cis to one another and MH is cytarabine; the 5′ oxygen of said cytarabine is attached to the phosphorus; V is 4-pyridyl; and pharmaceutically acceptable prodrugs and salts thereof.
1. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula III:
or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 , wherein said composition is suitable for oral administration, parenteral administration, administration by inhalation spray, topical administration, or rectal administration.
3. The pharmaceutical composition of claim 2 , wherein said composition is suitable for parenteral administration.
4. The pharmaceutical composition of claim 1 , wherein said composition is selected from the group consisting of aqueous isotonic sterile injection solutions, non-aqueous isotonic sterile injection solutions, aqueous sterile suspensions, and non-aqueous sterile suspensions.
5. The pharmaceutical composition of claim 1 , wherein said composition is in a form selected from the group consisting of tablets, troches, lozenges, aqueous suspensions, oil suspensions, dispersible powders and granules, oil-in-water emulsions, hard and soft capsules, syrups and elixirs, and sterile injectable preparations.
6. The pharmaceutical composition of claim 5 , wherein said composition is in the form of dispersible powders or granules.
7. The pharmaceutical composition of claim 5 , wherein said composition is in the form of a sterile injectable preparation.
8. The pharmaceutical composition of claim 7 , wherein said sterile injectable preparation is a sterile injectable solution or suspension.
9. The pharmaceutical composition of claim 3 , wherein said composition is an aqueous sterile solution suitable for intravenous administration.
10. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula III:
or a pharmaceutically acceptable salt thereof, and
a pharmaceutically effective amount of an oncolytic agent or salt thereof, wherein said composition is suitable for oral administration, parenteral administration, administration by inhalation spray, topical administration, or rectal administration.
11. The pharmaceutical composition of claim 10 , wherein said oncolytic agent is selected from the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide, thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin, daunorubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine, floxuridine, fluorouracil, thioguanine, methotrexate, mitomycin, etoposide, paclitaxel, docetaxel, irinotecan, topotecan, teniposide, nedaplatin, carmustine, doxifluridine, cladribine, fludarabine, mercaptopurine, azatoxin, camptothecin, lurtotecan, 9-aminocamptothecin, pirarubin, neocarzinostatin, calicheamicin, esperamicin, and luroteca.
12. The pharmaceutical composition of claim 10 , wherein said composition is suitable for parenteral administration.
13. The pharmaceutical composition of claim 10 , wherein said composition is selected from the group consisting of aqueous isotonic sterile injection solutions, non-aqueous isotonic sterile injection solutions, aqueous sterile suspensions, and non-aqueous sterile suspensions.
14. The pharmaceutical composition of claim 10 , wherein said composition is in a form selected from the group consisting of tablets, troches, lozenges, aqueous suspensions, oil suspensions, dispersible powders and granules, oil-in-water emulsions, hard and soft capsules, syrups and elixirs, and sterile injectable preparations.
15. The pharmaceutical composition of claim 14 , wherein said composition is in the form of dispersible powders or granules.
16. The pharmaceutical composition of claim 14 , wherein said composition is in the form of a sterile injectable preparation.
17. The pharmaceutical composition of claim 16 , wherein said sterile injectable preparation is a sterile injectable solution or suspension.
18. The pharmaceutical composition of claim 12 , wherein said composition is an aqueous sterile solution suitable for intravenous administration.
19. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula III:
or a pharmaceutically acceptable salt thereof, and
a pharmaceutically effective amount of an agent that induces P450 activity or salt thereof.
20. The pharmaceutical composition of claim 19 , wherein said agent that induces P450 activity is selected from the group consisting of rifampicin, a glucocorticoid, phenobarbital and erythromycin.
21. The pharmaceutical composition of claim 19 , wherein said composition further comprises a pharmaceutically acceptable excipient or diluent selected from the group consisting of sweetening agents, flavoring agents, coloring agents, preserving agents, inert diluents, granulating and disintegrating agents, binding agents, lubricating agents, suspending agents, and dispersing or wetting agents.
22. The pharmaceutical composition of claim 19 , wherein said composition is suitable for oral administration, parenteral administration, administration by inhalation spray, topical administration, or rectal administration.
23. The pharmaceutical composition of claim 22 , wherein said composition is suitable for parenteral administration.
24. The pharmaceutical composition of claim 23 , wherein said composition is selected from the group consisting of aqueous isotonic sterile injection solutions, non-aqueous isotonic sterile injection solutions, aqueous sterile suspensions, and non-aqueous sterile suspensions.
25. The pharmaceutical composition of claim 19 , wherein said composition is in a form selected from the group consisting of tablets, troches, lozenges, aqueous suspensions, oil suspensions, dispersible powders and granules, oil-in-water emulsions, hard and soft capsules, syrups and elixirs, and sterile injectable preparations.
26. The pharmaceutical composition of claim 25 , wherein said composition is in the form of dispersible powders or granules.
27. The pharmaceutical composition of claim 25 , wherein said composition is in the form of a sterile injectable preparation.
28. The pharmaceutical composition of claim 27 , wherein said sterile injectable preparation is a sterile injectable solution or suspension.
29. The pharmaceutical composition of claim 23 , wherein said composition is an aqueous sterile solution suitable for intravenous administration.